Ocugen Inc

NASDAQ:OCGNUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. The Company's technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. It is developing COVAXIN, which is a whole-virion inactivated intramuscular COVID-19 vaccine candidate for the North American market. It is also developing a inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. Its modifier gene therapy platform is focused on addressing various retinal diseases, including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), and Stargardt disease, with a single mutation-agnostic therapy.

Contact Information

Headquarters

11 GREAT VALLEY PARKWAYMALVERN, PA, United States 19355

Phone

484-328-4701

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer, Interim Principal Financial Officer

Shankar Musunuri

Principal Financial Officer, Interim Chief Accounting Officer

Michael Breininger

Chief Scientific Officer, Executive Officer

Arun Upadhyay

Independent Director

Kirsten Castillo

Independent Director

Prabhavathi Fernandes